Open AccessDenosumab for the treatment of bisphosphonate resistant hypercalcemia in a hemodialysis patient
Author(s) -
Omar Dahmani,
Christine Sophoclis,
Malika Kebir,
Djemai Bouguern,
A Sakho,
Pascale Demarchi
Publication year - 2017
Publication title -
saudi journal of kidney diseases and transplantation/našrat amraḍ wa zira'aẗ al-kulaẗ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.268
H-Index - 30
eISSN - 2320-3838
pISSN - 1319-2442
DOI - 10.4103/1319-2442.198239
Subject(s) - medicine , denosumab , hemodialysis , discontinuation , hyperparathyroidism , malignancy , vitamin d and neurology , calcitonin , gastroenterology , dialysis , primary hyperparathyroidism , urology , endocrinology , osteoporosis
The acronym of malignancy, iatrogenic, intoxication and immobilization, sarcoidosis, hyperparathyroidism and hyperthyroidism, milk-alkali syndrome, and paget is very helpful in diagnosing hypercalcemia. We report on a 94-year-old patient with history of end-stage renal failure secondary to benign nephroangiosclerosis, who was on maintenance hemodialysis during dialysis, his blood chemistry revealed mild hypercalcemia (2.66 mmol/L) with normal level of intact primary hyperparathyroidism (32.37 ng/mL) mandating the discontinuation of Vitamin D[3]. In view of persisting hypercalcemia, denosumab 60 mg/mL was administrated subcutaneously. The serum calcium level showed a decrease and stabilized at near upper limit (2.57 mmol/L). Three weeks later, the serum calcium remained mildly elevated fluctuating between 2.66 and 2.80 mmol/L.